Q-omics provides the consensus-scored NDUFB9 profile across patient tissues and cancer cell-line models. NDUFB9 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, NDUFB9 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, NDUFB9 protein abundance shows 21,995 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, HNSC, and GBM as cancer lineages where NDUFB9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NDUFB9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NDUFB9 survival associations across molecular data types. NDUFB9 RNA expression shows survival associations in the most cancer types (27), followed by mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NDUFB9 RNA expression–survival associations across cancer types. High NDUFB9 expression shows unfavorable associations in UVM, SKCM, ACC, UCEC and UCS, but favorable associations in LGG. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for NDUFB9 RNA expression.
This table summarizes NDUFB9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NDUFB9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NDUFB9 shows lower tumor expression in KIRC and higher tumor expression in HNSC, LIHC, LUSC, BRCA and STAD. The HNSC box plot shows higher NDUFB9 RNA expression in tumor versus normal tissue (log2 FC = +0.639, t-test p < 0.001).
This table shows molecular features associated with NDUFB9 in patient tissues and cancer cell lines. In patient samples, NDUFB9 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NDUFB9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
